Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Kaposi's sarcoma in AIDS. 70 cases].

A Lafeuillade1, I Poizot-Martin, C Dhiver

  • 1Clinique des Maladies du Sang, Institut Paoli-Calmettes, Marseille.

Presse Medicale (Paris, France : 1983)
|January 26, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort.

BMC infectious diseases·2019
Same author

Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. Results from the French Hospital Database on HIV (FHDH)-Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) CO4 cohort study.

HIV medicine·2019
Same author

Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France.

Medecine et maladies infectieuses·2018
Same author

HIV infection and care pathway: From guidelines to clinical practice.

Medecine et maladies infectieuses·2018
Same author

Risk of diabetes in HIV-infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohort.

Alimentary pharmacology & therapeutics·2018

Kaposi's sarcoma is a frequent cancer in AIDS patients, but its treatment is not standardized. Visceral lesions impact survival, though opportunistic infections cause most deaths, highlighting the need for better therapeutic strategies.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Immunology

Context:

  • Kaposi's sarcoma (KS) is the most common malignancy in Acquired Immunodeficiency Syndrome (AIDS).
  • KS was one of the first recognized manifestations of AIDS.
  • Management of KS in AIDS patients remains a significant clinical challenge.

Purpose:

  • To analyze the clinical characteristics, treatment modalities, and outcomes of Kaposi's sarcoma in a cohort of 70 Acquired Immunodeficiency Syndrome patients.
  • To evaluate the impact of visceral lesions on survival in AIDS-related Kaposi's sarcoma.
  • To identify challenges in diagnosing and treating Kaposi's sarcoma in the context of underlying immunodeficiency.

Summary:

  • A study of 70 Acquired Immunodeficiency Syndrome patients with Kaposi's sarcoma between 1985 and 1989 found a mean of 15 months between HIV diagnosis and KS diagnosis.

Related Experiment Videos

  • Visceral lesions were present in 50% of patients, significantly reducing survival time.
  • Treatments included chemotherapy (55 cases), interferon-alpha (23 cases), and radiotherapy (13 cases). Deaths were primarily due to opportunistic infections.

    • Impact:

    • The study underscores the diagnostic difficulties posed by atypical Kaposi's sarcoma forms and the therapeutic challenges due to immunodepression in AIDS patients.
    • Findings suggest a need for standardized treatment protocols and highlight the critical role of opportunistic infections in mortality.
    • The authors advocate for multicenter trials to establish optimal therapeutic approaches for AIDS-related Kaposi's sarcoma.